Viridian completes subject enrolment for Phase III trial of TED treatment
Viridian Therapeutics has announced the completion of subject enrolment for its Phase III THRIVE-2 clinical trial of VRDN-001, aimed at…
Viridian Therapeutics has announced the completion of subject enrolment for its Phase III THRIVE-2 clinical trial of VRDN-001, aimed at…
Alkeus Pharmaceuticals has reported the latest interim data from TEASE-3 trial where gildeuretinol acetate demonstrated to stall the progression of…
Roche has announced four-year results from the RHONE-X extension study, which evaluated the long-term safety and efficacy of Vabysmo (faricimab)…
Aldeyra Therapeutics has concluded the subject enrolment in its Phase III clinical trial of topical ocular 0.25% reproxalap, a new…
US-based biotechnology company Viridian Therapeutics has announced plans to begin two Phase III clinical trials of the anti-IGF-1R antibody, VRDN-003,…
Stealth BioTherapeutics has enrolled the first subject in the Phase III ReNEW clinical trial as part of a clinical programme…
HanAll Biopharma has commenced the Phase III VELOS-4 trial for tanfanercept, a new topical anti-inflammatory treatment for moderate to severe…
Boehringer Ingelheim has reported positive data from the HORNBILL Phase I/IIa clinical trial of the humanised monoclonal anti-Sema3A antibody, BI…
Aurion Biotech has announced the completion of dosing for all participants in the Phase I/II CLARA clinical trial of allogeneic…
US-based Sight Sciences has published the two-year post-surgical outcomes of its minimally invasive glaucoma surgery device, the OMNI surgical system.…